Recent News

• 11.04.2026 - ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
• 10.28.2026 - ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
• 10.15.2026 - ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
• 08.05.2026 - ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.29.2026 - ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
• 05.06.2026 - ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• 05.04.2026 - ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
• 04.29.2026 - ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
• 03.27.2026 - ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
• 03.25.2026 - ADMA Biologics Addresses Misleading Short-Seller Report

Recent Filings

• 11.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2026 - 8-K Current report
• 11.04.2026 - EX-99.1 EX-99.1
• 08.07.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2026 - 8-K Current report
• 08.05.2026 - EX-99.1 EX-99.1
• 07.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 8-K Current report